DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Graf, Franziska ^a   Fahrer, Jörg ^a   Maus, Stephan ^a   Morgenstern, Alfred ^b   Bruchertseifer, Frank ^b   Venkatachalam, Senthil ^a   Fottner, Christian ^a   Weber, Matthias M ^a   Huelsenbeck, Johannes ^a   Schreckenberger, Mathias ^a   Kaina, Bernd ^a   Miederer, Matthias ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b JOINT RESEARCH CENTRE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACTINIUM 225; DOUBLE STRANDED DNA; LUTETIUM 177; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; ACTINIUM; LUTETIUM; RADIOISOTOPE;

ALPHA RADIATION; APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CYTOTOXICITY; DNA STRAND BREAKAGE; FLOW CYTOMETRY; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; PROTEIN PHOSPHORYLATION; TUMOR CELL; TUMOR GROWTH; ANIMAL; CELL DEATH; DOUBLE STRANDED DNA BREAK; GENETICS; METABOLISM; NEUROENDOCRINE TUMORS; PATHOLOGY; RADIATION RESPONSE; RAT; THERAPEUTIC USE; TUMOR CELL LINE;

ACTINIUM; ALPHA PARTICLES; ANIMALS; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; DNA BREAKS, DOUBLE-STRANDED; LUTETIUM; NEUROENDOCRINE TUMORS; RADIOISOTOPES; RATS; RECEPTORS, SOMATOSTATIN;

EID: 84895763591     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088239     Document Type: Article

References (31)

1. Kam BL, Teunissen JJ, Krenning EP, de Herder WW, Khan S, et al. (2012) Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging 39 Suppl 1: S103-112.
2. Reubi JC (2003) Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24: 389-427.
3. McDevitt MR, Sgouros G, Finn RD, Humm JL, Jurcic JG, et al. (1998) Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med 25: 1341-1351. (Pubitemid 28446064)
4. Dadachova E (2010) Cancer therapy with alpha-emitters labeled peptides. Semin Nucl Med 40: 204-208.
5. Morgenstern A, Bruchertseifer F, Apostolidis C (2011) Targeted alpha therapy with 213Bi. Curr Radiopharm 4: 295-305.
6. Miederer M, Scheinberg DA, McDevitt MR (2008) Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications. Adv Drug Deliv Rev 60: 1371-1382.
7. Song H, Hobbs RF, Vajravelu R, Huso DL, Esaias C, et al. (2009) Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y. Cancer Res 69: 8941-8948.
8. Essler M, Gartner FC, Neff F, Blechert B, Senekowitsch-Schmidtke R, et al. (2012) Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis. Eur J Nucl Med Mol Imaging 39: 602-612.
9. Miederer M, Henriksen G, Alke A, Mossbrugger I, Quintanilla-Martinez L, et al. (2008) Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors. Clin Cancer Res 14: 3555-3561.
10. Friesen C, Glatting G, Koop B, Schwarz K, Morgenstern A, et al. (2007) Breaking chemoresistance and radioresistance with [213Bi]anti-CD45 antibodies in leukemia cells. Cancer Res 67: 1950-1958. (Pubitemid 46424211)
11. Roscher M, Hormann I, Leib O, Marx S, Moreno J, et al. (2013) Targeted alpha-therapy using [Bi-213]anti-CD20 as novel treatment option for radio- and chemoresistant non-Hodgkin lymphoma cells. Oncotarget 4: 218-230.
12. Chu J, Ji H, Lu M, Li Z, Qiao X, et al. (2013) Proteomic analysis of apoptotic and oncotic pancreatic acinar AR42J cells treated with caerulein. Mol Cell Biochem 382: 1-17.
13. Apostolidis C, Molinet R, Rasmussen G, Morgenstern A (2005) Production of Ac-225 from Th-229 for targeted alpha therapy. Anal Chem 77: 6288-6291. (Pubitemid 41436964)
14. Olive PL, Banath JP (2006) The comet assay: a method to measure DNA damage in individual cells. Nat Protoc 1: 23-29.
15. Tice RR, Agurell E, Anderson D, Burlinson B, Hartmann A, et al. (2000) Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 35: 206-221. (Pubitemid 30196665)
16. Olive PL, Banath JP, Durand RE (1990) Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the "comet" assay. Radiat Res 122: 86-94. (Pubitemid 20130057)
17. Thompson LH (2012) Recognition, signaling, and repair of DNA double-strand breaks produced by ionizing radiation in mammalian cells: the molecular choreography. Mutat Res 751: 158-246.
18. Bakkenist CJ, Kastan MB (2003) DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421: 499-506. (Pubitemid 36168436)
19. Derheimer FA, Kastan MB (2010) Multiple roles of ATM in monitoring and maintaining DNA integrity. FEBS Lett 584: 3675-3681.
20. Kinner A, Wu W, Staudt C, Iliakis G (2008) Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res 36: 5678-5694.
21. White JS, Yue N, Hu J, Bakkenist CJ (2011) The ATM kinase signaling induced by the low-energy beta-particles emitted by (33)P is essential for the suppression of chromosome aberrations and is greater than that induced by the energetic beta-particles emitted by (32)P. Mutat Res 708: 28-36.
22. Meyer B, Voss KO, Tobias F, Jakob B, Durante M, et al. (2013) Clustered DNA damage induces pan-nuclear H2AX phosphorylation mediated by ATM and DNA-PK. Nucleic Acids Res 41: 6109-6118.
23. Wu J, Clingen PH, Spanswick VJ, Mellinas-Gomez M, Meyer T, et al. (2013) gamma-H2AX foci formation as a pharmacodynamic marker of DNA damage produced by DNA cross-linking agents: results from 2 phase I clinical trials of SJG-136 (SG2000). Clin Cancer Res 19: 721-730.
24. Staaf E, Brehwens K, Haghdoost S, Czub J, Wojcik A (2012) Gamma-H2AX foci in cells exposed to a mixed beam of X-rays and alpha particles. Genome Integr 3: 8.
25. Nayak TK, Norenberg JP, Anderson TL, Prossnitz ER, Stabin MG, et al. (2007) Somatostatin-receptor-targeted alpha-emitting 213Bi is therapeutically more effective than beta(-)-emitting 177Lu in human pancreatic adenocarcinoma cells. Nucl Med Biol 34: 185-193. (Pubitemid 46241895)
26. Behr TM, Behe M, Stabin MG, Wehrmann E, Apostolidis C, et al. (1999) High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model. Cancer Res 59: 2635-2643. (Pubitemid 29269111)
27. Repetto-Llamazares AH, Larsen RH, Mollatt C, Lassmann M, Dahle J (2013) Biodistribution and dosimetry of (177)Lu-tetulomab, a new radioimmunoconjugate for treatment of non-Hodgkin lymphoma. Curr Radiopharm 6: 20-27.
28. Sgouros G, Roeske JC, McDevitt MR, Palm S, Allen BJ, et al. (2010) MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med 51: 311-328.
29. McDevitt MR, Ma D, Lai LT, Simon J, Borchardt P, et al. (2001) Tumor therapy with targeted atomic nanogenerators. Science 294: 1537-1540. (Pubitemid 33063927)
30. Xue D, Zhang W, Liang T, Zhao S, Sun B, et al. (2009) Effects of arsenic trioxide on the cerulein-induced AR42J cells and its gene regulation. Pancreas 38: e183-189.
31. Haro KJ, Scott AC, Scheinberg DA (2012) Mechanisms of resistance to high and low linear energy transfer radiation in myeloid leukemia cells. Blood 120: 2087-2097.